Investigational Site Number: 3760001

Ramat Gan 5266202

2 studies enrolling now · 6 studies all time

What they study most

Dermatitis Atopic, Hemophilia, Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC), Primary Progressive Multiple Sclerosis, Type 1 Diabetes, Type 1 Diabetes Mellitus

Studies at this site

• A Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to 25 Years of Age With Stage 3 Type 1 Diabetes — Recruiting now
• Long-Term Outcomes of Teplizumab in Routine Clinical Care — Recruiting now
• Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (PERSEUS) — Completed
• Long-term Safety and Efficacy Study of Fitusiran in Patients With Hemophilia A or B, With or Without Inhibitory Antibodies to Factor VIII or IX — Running, not enrolling
• Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Platinum-based Chemotherapy With or Without Pemetrexed in Patients With NSQ NSCLC — Stopped early
• Observational Evaluation of Atopic Dermatitis in Pediatric Patients — Running, not enrolling